SUMOylation of linker histone H1 drives chromatin condensation and restriction of embryonic cell fate identity.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
06 01 2022
Historique:
received: 18 01 2021
revised: 08 11 2021
accepted: 10 11 2021
pubmed: 8 12 2021
medline: 15 2 2022
entrez: 7 12 2021
Statut: ppublish

Résumé

The fidelity of the early embryonic program is underlined by tight regulation of the chromatin. Yet, how the chromatin is organized to prohibit the reversal of the developmental program remains unclear. Specifically, the totipotency-to-pluripotency transition marks one of the most dramatic events to the chromatin, and yet, the nature of histone alterations underlying this process is incompletely characterized. Here, we show that linker histone H1 is post-translationally modulated by SUMO2/3, which facilitates its fixation onto ultra-condensed heterochromatin in embryonic stem cells (ESCs). Upon SUMOylation depletion, the chromatin becomes de-compacted and H1 is evicted, leading to totipotency reactivation. Furthermore, we show that H1 and SUMO2/3 jointly mediate the repression of totipotent elements. Lastly, we demonstrate that preventing SUMOylation on H1 abrogates its ability to repress the totipotency program in ESCs. Collectively, our findings unravel a critical role for SUMOylation of H1 in facilitating chromatin repression and desolation of the totipotent identity.

Identifiants

pubmed: 34875212
pii: S1097-2765(21)00990-4
doi: 10.1016/j.molcel.2021.11.011
pii:
doi:

Substances chimiques

Chromatin 0
Histones 0
SUMO2 protein, mouse 0
Small Ubiquitin-Related Modifier Proteins 0
Sumo3 protein, mouse 0
Ubiquitins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-122.e9

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM138386
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interests The authors declare no competing interests.

Auteurs

Daoud Sheban (D)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Tom Shani (T)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Roey Maor (R)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Alejandro Aguilera-Castrejon (A)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Nofar Mor (N)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Bernardo Oldak (B)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Merav D Shmueli (MD)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Avital Eisenberg-Lerner (A)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Jonathan Bayerl (J)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Jakob Hebert (J)

Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA.

Sergey Viukov (S)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Guoyun Chen (G)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Assaf Kacen (A)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Vladislav Krupalnik (V)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Valeriya Chugaeva (V)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Shadi Tarazi (S)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Alejandra Rodríguez-delaRosa (A)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Mirie Zerbib (M)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Adi Ulman (A)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Solaiman Masarwi (S)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.

Meital Kupervaser (M)

De Botton Institute for Protein Profiling, INCPM, Weizmann Institute of Science, Rehovot 7610001, Israel.

Yishai Levin (Y)

De Botton Institute for Protein Profiling, INCPM, Weizmann Institute of Science, Rehovot 7610001, Israel.

Efrat Shema (E)

Department of Biological Regulation, Weizmann Institute of Science, Rehovot 7610001, Israel.

Yael David (Y)

Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional PhD Program in Chemical Biology, New York, NY, USA.

Noa Novershtern (N)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel.

Jacob H Hanna (JH)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: jacob.hanna@weizmann.ac.il.

Yifat Merbl (Y)

Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: yifat.merbl@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH